Agilon Health remains a top idea for 2023 at William Blair

William Blair analyst Ryan Daniels attributes Agilon Health’s relative share outperformance year-to-date to several recent operational highlights, including strong sales and EBITDA performance and stronger than anticipated new provider adds. In addition to a capital-light model, the company’s "favorable" end-market trends, "robust" growth outlook and "pristine" balance sheet are attractive to both near- and longer-term investors, the analyst tells investors in a research note. The firm believes some investors still underappreciate the Agilon story, especially as it relates to management’s long-term outlook. It says the stock remains a top idea for 2023 with an Outperform rating.